Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial)
暂无分享,去创建一个
M. Nagino | Hidenari Goto | T. Mukai | T. Ebata | K. Uehara | K. Hiramatsu | A. Maeda | E. Sakamoto | Y. Okada | Satoshi Kobayashi | E. Takeuchi
[1] B. Xiong,et al. Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: A meta-analysis. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[2] E. Hatano,et al. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐ras status for unresectable colorectal liver metastasis (BECK study) , 2015, Journal of hepato-biliary-pancreatic sciences.
[3] H. Yatsuya,et al. Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: survival analysis of N-SOG 01 trial , 2015, Cancer Chemotherapy and Pharmacology.
[4] D. Shin,et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial , 2014, BMC Cancer.
[5] T. Hickish,et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. , 2014, The Lancet. Oncology.
[6] H. Kijima,et al. Evaluation of the Usefulness of the Indocyanine Green Clearance Test for Chemotherapy-Associated Liver Injury in Patients with Colorectal Cancer Liver Metastasis , 2014, Annals of surgical oncology.
[7] PhD Hiroyuki Uetake MD,et al. A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808) , 2014, Annals of Surgical Oncology.
[8] Kazuhiro Yoshida,et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. , 2013, The Lancet. Oncology.
[9] R. Parks,et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.
[10] F. Izzo,et al. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial , 2013, British Journal of Cancer.
[11] M. Nagino,et al. Phase II Trial of Adjuvant Chemotherapy with S-1 for Colorectal Liver Metastasis , 2013, Annals of surgical oncology.
[12] M. Makuuchi,et al. Liver Resection for Multiple Colorectal Liver Metastases with Surgery Up-front Approach: Bi-institutional Analysis of 736 Consecutive Cases , 2012, World Journal of Surgery.
[13] T. Hickish,et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] W. Scheithauer,et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results , 2011, British Journal of Cancer.
[15] Masahiro Yoshida,et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer , 2011, International Journal of Clinical Oncology.
[16] T. Gruenberger,et al. Evaluation of Chemotherapy-Associated Liver Injury in Patients with Colorectal Cancer Liver Metastases Using Indocyanine Green Clearance Testing , 2011, Annals of Surgical Oncology.
[17] P. Colombo,et al. Is Perioperative Chemotherapy Useful for Solitary, Metachronous, Colorectal Liver Metastases? , 2010, Annals of surgery.
[18] M. Makuuchi,et al. Recovery of Liver Function After the Cessation of Preoperative Chemotherapy for Colorectal Liver Metastasis , 2010, Annals of Surgical Oncology.
[19] J. Weitz,et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. , 2010, The Lancet. Oncology.
[20] R. Seshadri,et al. Endobiliary Metastasis from Rectal Cancer Mimicking Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature , 2009, Journal of gastrointestinal cancer.
[21] A. Zhu,et al. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. , 2009, The oncologist.
[22] T. Gruenberger,et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[23] Thomas Gruenberger,et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.
[24] P. Tekkis,et al. Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer: A Multifactorial Model of 929 Patients , 2008, Annals of surgery.
[25] K. McMasters,et al. Preoperative Chemotherapy Does Not Increase Morbidity or Mortality of Hepatic Resection for Colorectal Cancer Metastases , 2008, Annals of Surgical Oncology.
[26] L. Ellis,et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases , 2007, Cancer.
[27] J. Bosset,et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] B. Nordlinger,et al. Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases , 2006, Annals of surgery.
[29] Evelyne M. Loyer,et al. Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases , 2005, Annals of surgery.
[30] P. Chow,et al. Clinical mimicry of hepatocellular carcinoma: imaging-pathological correlation. , 2005, Singapore medical journal.
[31] F. Lévi,et al. Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases? , 2004, Annals of surgery.
[32] Michael A. Choti,et al. Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases , 2002, Annals of surgery.
[33] L H Blumgart,et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.
[34] O. Dworak,et al. Pathological features of rectal cancer after preoperative radiochemotherapy , 1997, International Journal of Colorectal Disease.
[35] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.